Article
Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.
PloS one - 1 Jan 2013
Mielke Michelle M, Maetzler Walter, Haughey Norman J, Bandaru Veera V R, Savica Rodolfo, Deuschle Christian, Gasser Thomas, Hauser Ann-Kathrin, Gräber-Sultan Susanne, Schleicher Erwin, Berg Daniela, Liepelt-Scarfone Inga
Abstract excerpt
BACKGROUND: Mutations in the gene coding for glucocerebrosidase (GBA), which metabolizes glucosylceramide (a monohexosylceramide) into glucose and ceramide, is the most common genetic risk factor for sporadic Parkinson's disease (PD). GBA mutation carriers are more likely to have an earlier age of onset and to develop cognitive impairment and dementia. We hypothesized that plasma levels of lipids involved in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.